




530 Rec'd FTO

PCT # S.
07 JUN 2002
A20UNITED STATES PATENT AND TRADEMARK OFFICEIn re United States Patent Application of:

Applicant:	Michaela Arndt	Docket No.:	4121-135
Application No.:	10/049,404	Examiner:	Not yet assigned.
Date Filed:	February 5, 2002	Group Art Unit:	Not yet assigned.
Title:	F_v ANTIBODY CONSTRUCT COMPRISING BINDING SITES FOR A CD16 RECEPTOR AND A CD30 SURFACE PROTEIN		

FIRST CLASS MAIL CERTIFICATE

I hereby certify that I am mailing the attached documents to the Commissioner for Patents on the date specified, in an envelope addressed to the Commissioner for Patents, Washington, DC 20231, and First Class Mailed under the provisions of 37 CFR 1.8.



Blake Crouch

May 30, 2002

Date of Mailing

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:


Pursuant to 37 C.F.R. §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. One copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- ☒ 1. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.
- ☐ 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart

foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).

- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).
- ☐ c. Attached is our check no. _____ in the amount of \$_____ in payment of the fee under 37 C.F.R. §1.17(p). Please credit or debit Deposit Account No. _____ as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.
- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered. Attached is our check no. _____ in the amount of \$130.00 in payment of the petition fee under 37 C.F.R. §1.17(i)(1). Please credit or debit Deposit Account No. _____ as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).

Respectfully submitted,



Marianne Fuierer
Reg. No. 39,983
Attorney for Applicant

INTELLECTUAL PROPERTY/
TECHNOLOGY LAW
P.O. Box 14329
Research Triangle Park, NC 27709
Telephone: (919) 419-9350
Fax: (919) 419-9354
Attorney Ref: 4121-135

FORM PTO-1449		US Dept. of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO. 4121-135		SERIAL NO. 10/049,404	
INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)				APPLICANT Michaela Arndt			
				FILING DATE February 5, 2002		GROUP Not yet assigned.	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,643,759	7/1/97	Pfreundschuh			
	AB	6,294,167	9/25/01	Lindhofer et al.			
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AC	DE 43 37 197	10/30/93	Germany			
	AD	DE 195 31 346	8/25/95	Germany			
	AE	DE 198 38 967	2/6/98	Germany			
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
	AF	XP-002115487. "Bispecific CD3 X CD19 Diabody for T Cell-Mediated Lysis of Malignant Human B Cells." Kipriyanov et al. Int. J. Cancer: 77, 763-771 (1998).					
	AG	"Anti- CD16/CD30 bispecific antibodies as possible treatment for refractory Hodgkin's Disease." Hartmann et al., Leuk & Lymph., 1998. Vol 31. patent. 385-392.					
	AH	XP 000653169. 609. Klimka et al.					
	AI	XP-002153101. "A bispecific diabody that mediates natural killer cell cytotoxicity against exnotransplantated human Hodgkin's tumors." Arndt et al. Blood, Vol. 94, No. 8 (October 15), 1999: patent 2562-2568.					
EXAMINER					DATE CONSIDERED		